Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat inflammatory and metabolic diseases. Its product pipeline includes CAT-1004, an oral small molecule that has completed Phase 1 clinical trials for the treatment of duchenne muscular dystrophy (DMD); CAT-2054, which is in Phase I clinical trial for the treatment of hypercholesterolemia in patients for whom existing treatments are insufficient; and CAT-2003 that has completed Phase IIa trials for the treatment of patients with elevated triglycerides or hypertriglyceridemia. It is also developing CAT-4001 that is in preclinical stage for the treatment for severe, rare neurodegenerative diseases, such as Friedreich's ataxia and amyotrophic lateral sclerosis. The company has collaboration agreements with dystrophy association for the development of CAT-1004, a treatment for DMD; and Sarepta Therapeutics, Inc. to explore a combination drug treatment approach for DMD. Catabasis Pharmaceuticals, Inc. was founded in 2008 and is based in Cambridge, Massachusetts.